Skip to main content
Premium Trial:

Request an Annual Quote

BGI to Launch Desktop Sequencer in October; Instrument Will Run NIFTY Noninvasive Prenatal Test

NEW YORK (GenomeWeb) – BGI said late last week that it plans to launch a desktop sequencer called BGISEQ-500 in October.

BGISEQ-500 will be based on Complete Genomics' technology and will automate sample preparation, sequencing, and data analysis.

BGI also plans to run its noninvasive prenatal test, NIFTY, on the new instrument. Turnaround time for the test, from library construction to data analysis, will be 24 hours, and each run will multiplex between 16 and 192 samples.

A year ago, the China Food and Drug Administration approved the NIFTY test on two sequencing platforms — BGISEQ-100 and BGISEQ-1000 — which are based on Thermo Fisher Scientific's Ion Torrent platform and Complete Genomics' technology, respectively.

BGI said it will make more details about the BGISEQ-500 instrument available during the 10th International Conference on Genomics in Shenzhen in October.

The company announced in January that it plans to commercialize two next-gen sequencing systems — a large-scale platform and a desktop instrument — this year but provided no further details at the time.

Earlier this month, it provided first details on Revolocity, a high-throughput sequencing system that will initially be able to sequence 10,000 human genomes per year and has a list price of $12 million.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.